BPC-157: Chemical Properties
30 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: February 2026
Chemical Properties
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1419.556 g/mol |
| CAS Number | 137525-51-0 |
| Sequence (3-Letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Sequence (1-Letter) | GEPPPGKPADDAGLV |
| Amino Acids | 15 (linear pentadecapeptide) |
| Structural Type | Linear pentadecapeptide, no disulfide bridges, polyproline II helix |
| Parent Molecule | Body Protection Compound (BPC) from human gastric juice |
| Synonyms | Bepecin, PL 14736, PL-10, PLD-116, PCO-02 |
| Plasma Half-Life | <30 minutes (IV/IM) |
Identifiers
| PubChem CID | 9941957 |
| InChI Key | HEEWEZGQMLZMFE-RKGINYAYSA-N |
| Isomeric SMILES | C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN |
| Drug Codes | PL 14736, PL-10, PLD-116, PCO-02, Bepecin |
References
- Sikiric P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology-Paris. 1993;87(5):313-327.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response. Current Pharmaceutical Design. 2020;26(25):3024-3044.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov. Updated 2023.
- World Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
- Ruenzi M, et al. BPC-157 in patients with ulcerative colitis: A Phase II multicenter, randomized, double-blind, placebo-controlled study. Gastroenterology. 2005;128(Suppl 2):A-585.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect. Current Pharmaceutical Design. 2025.
- Xu C, et al. Preclinical safety evaluation of body protection compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665.
- Hsieh MJ, et al. BPC157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2020;25(21):5159.
- Schlosser N. BPC-157: A Polyproline II Helix Engages SH3 Domains of Src Family Kinases. 2025.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
- Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.
- Vukojevic J, et al. Rat inferior caval vein (ICV) ligature and BPC 157. Molecular Neurobiology. 2020;57:4029-4044.
- Sikiric P, et al. The pharmacological properties of the novel peptide BPC 157. Inflammopharmacology. 1999;7(1):1-14.
- Zemba Cilic A, et al. Stable gastric pentadecapeptide BPC 157 and dopamine system. Current Neuropharmacology. 2021;19(11):1696-1714.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983.
- Matek D, et al. BPC 157 counteracts muscle-to-bone detachment: Oral application evidence. Biomedicine & Pharmacotherapy. 2025.
- Tudor M, et al. The gastroprotective and neuroprotective pentadecapeptide BPC 157 in the treatment of traumatic brain injury in rats. Regulatory Peptides. 2010;160(1-3):26-32.
- Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury. Journal of Orthopaedic Surgery and Research. 2019;14:440.
- Sikiric P, et al. Vascular occlusion and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2022;28(25):2082-2093.
- Masnec S, et al. Stable gastric pentadecapeptide BPC 157 heals corneal injuries. Current Pharmaceutical Design. 2015;21(33):4868-4875.
- Sever M, et al. Stable gastric pentadecapeptide BPC 157 counteracts liver fibrosis. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
- Lee E, Padgett B. BPC-157 and knee pain: A retrospective chart review. Alternative Therapies in Health and Medicine. 2021.
- Lee E, Walker C, Ayadi B. BPC-157 intravesical therapy for interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine. 2024.
- He Y, et al. Pharmacokinetics and excretion study of BPC157 in rats and dogs. Journal of Chromatography B. 2022;1201:123300.
- Veljaca M, et al. BPC-157: Safety and pharmacokinetics after rectal administration in healthy male volunteers. Gut. 2003;52(Suppl VI):A246.
- Lee E, Burgess K. Intravenous BPC-157 in healthy adults: A pilot tolerability study. Alternative Therapies in Health and Medicine. 2025.
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: GI Tract Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989.
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.
Related Research Questions
Want the complete research review?
View Full BPC-157 Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.